MA31805B1 - Molécules améliorées de liaison à nogo-a et utilisation pharmaceutique de celles-ci - Google Patents

Molécules améliorées de liaison à nogo-a et utilisation pharmaceutique de celles-ci

Info

Publication number
MA31805B1
MA31805B1 MA32813A MA32813A MA31805B1 MA 31805 B1 MA31805 B1 MA 31805B1 MA 32813 A MA32813 A MA 32813A MA 32813 A MA32813 A MA 32813A MA 31805 B1 MA31805 B1 MA 31805B1
Authority
MA
Morocco
Prior art keywords
binding molecule
nogo
protein
nervous system
molecules bind
Prior art date
Application number
MA32813A
Other languages
Arabic (ar)
English (en)
Inventor
Carmen Barske
Stefan Frentzel
Anis Khurso Mir
Martin E Schwab
Alessandra Vitaliti
Original Assignee
Novartis Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31805(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag
Publication of MA31805B1 publication Critical patent/MA31805B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur une molécule de liaison qui est capable de se lier au polypeptide nogoa humain ou au nig humain avec une constante de dissociation < 1 000 nm ; sur un polynucléotide codant pour une telle molécule de liaison ; sur un vecteur d'expression comprenant ledit polynucléotide ; sur un système d'expression comprenant un polynucléotide capable de produire une molécule de liaison ; sur une cellule hôte isolée qui comprend un système d'expression tel que défini ci-dessus ; sur l'utilisation d'une molécule de liaison comme produit pharmaceutique, notamment dans le traitement d'une maladie du système nerveux périphérique (snp) et/ou central (snc) ; sur une composition pharmaceutique comprenant ladite molécule de liaison ; et sur un procédé de traitement d'une maladie du système nerveux périphérique (snp) et/ou central (snc).
MA32813A 2007-11-02 2010-04-30 Molécules améliorées de liaison à nogo-a et utilisation pharmaceutique de celles-ci MA31805B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US174107P 2007-11-02 2007-11-02
EP07119847 2007-11-02
PCT/EP2008/064501 WO2009056509A1 (fr) 2007-11-02 2008-10-27 Molécules améliorées de liaison à nogo-a et utilisation pharmaceutique de celles-ci

Publications (1)

Publication Number Publication Date
MA31805B1 true MA31805B1 (fr) 2010-10-01

Family

ID=39156235

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32813A MA31805B1 (fr) 2007-11-02 2010-04-30 Molécules améliorées de liaison à nogo-a et utilisation pharmaceutique de celles-ci

Country Status (31)

Country Link
US (2) US8163285B2 (fr)
EP (1) EP2207808B1 (fr)
JP (1) JP5698534B2 (fr)
KR (1) KR101574814B1 (fr)
CN (1) CN101910200B (fr)
AR (1) AR072934A1 (fr)
AU (1) AU2008317724B2 (fr)
BR (1) BRPI0818928B1 (fr)
CA (1) CA2704357C (fr)
CL (1) CL2008003240A1 (fr)
CO (1) CO6270357A2 (fr)
CY (1) CY1114345T1 (fr)
DK (1) DK2207808T3 (fr)
ES (1) ES2425768T3 (fr)
HK (1) HK1143597A1 (fr)
HR (1) HRP20130699T1 (fr)
IL (2) IL205357A (fr)
JO (1) JO2876B1 (fr)
MA (1) MA31805B1 (fr)
MX (1) MX2010004831A (fr)
MY (1) MY149546A (fr)
NZ (1) NZ584911A (fr)
PE (1) PE20090981A1 (fr)
PL (1) PL2207808T3 (fr)
PT (1) PT2207808E (fr)
RU (1) RU2513697C2 (fr)
SI (1) SI2207808T1 (fr)
TN (1) TN2010000199A1 (fr)
TW (1) TWI429656B (fr)
WO (1) WO2009056509A1 (fr)
ZA (1) ZA201002799B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012004773A1 (fr) 2010-07-09 2012-01-12 Universite De Geneve Nouvelles utilisations d'inhibiteurs de nogo-a et procédés associés
WO2014006105A1 (fr) 2012-07-05 2014-01-09 Glaxo Group Limited Régime posologique optimal d'un anticorps anti-nogo-a dans le traitement de la sclérose latérale amyotrophique
CR20180234A (es) 2015-11-03 2018-09-11 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
CN114599676A (zh) 2019-10-24 2022-06-07 诺华康制药股份公司 新型抗-Nogo-A抗体
WO2024041450A1 (fr) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 Anticorps pour reconnaître de manière spécifique nogo-a et son utilisation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0383417B1 (fr) 1989-02-13 1995-12-27 Schering Aktiengesellschaft Activateur du plasminogène salivaires de chauve-souris vPA-alpha 1
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
SK287323B6 (sk) * 1998-11-06 2010-07-07 University Of Z�Rich Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie
CN1234730C (zh) * 2001-12-30 2006-01-04 上海中科伍佰豪生物工程有限公司 鼠抗氯霉素单克隆抗体及其用途
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
DK1639011T3 (da) 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
GB0329684D0 (en) * 2003-12-22 2004-01-28 Glaxo Group Ltd Method
TWI329649B (en) * 2003-12-22 2010-09-01 Glaxo Group Ltd Immunoglobulins
WO2006028197A1 (fr) 2004-09-06 2006-03-16 Kirin Beer Kabushiki Kaisha Anticorps anti-a33
ES2391902T3 (es) * 2005-07-05 2012-11-30 Glaxo Group Limited Anticuerpos humanizados específicos para NOGO-A y sus usos farmacéuticos
GB0525662D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US8071103B2 (en) 2006-07-18 2011-12-06 Centocor, Inc. Pharmaceutical composition comprising a human GLP-1 mimetibody
CL2008003241A1 (es) 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
KR101039751B1 (ko) 2008-10-16 2011-06-09 한국생명공학연구원 Ｔｍｐｒｓｓ４―특이적인 인간항체

Also Published As

Publication number Publication date
PE20090981A1 (es) 2009-08-13
IL205357A0 (en) 2010-12-30
BRPI0818928B1 (pt) 2021-12-07
CA2704357A1 (fr) 2009-05-07
JO2876B1 (en) 2015-03-15
IL221723A (en) 2014-08-31
CY1114345T1 (el) 2016-08-31
ZA201002799B (en) 2011-01-26
EP2207808B1 (fr) 2013-05-08
US20110027284A1 (en) 2011-02-03
JP5698534B2 (ja) 2015-04-08
MX2010004831A (es) 2010-05-21
US20120171215A1 (en) 2012-07-05
IL205357A (en) 2014-08-31
WO2009056509A1 (fr) 2009-05-07
KR20100100848A (ko) 2010-09-15
CA2704357C (fr) 2016-06-21
MY149546A (en) 2013-09-13
PT2207808E (pt) 2013-08-26
CN101910200B (zh) 2013-12-18
CN101910200A (zh) 2010-12-08
IL221723A0 (en) 2012-10-31
TW200934791A (en) 2009-08-16
ES2425768T3 (es) 2013-10-17
AU2008317724A1 (en) 2009-05-07
US8758754B2 (en) 2014-06-24
TN2010000199A1 (en) 2011-11-11
CL2008003240A1 (es) 2009-06-05
TWI429656B (zh) 2014-03-11
HK1143597A1 (en) 2011-01-07
JP2011502476A (ja) 2011-01-27
DK2207808T3 (da) 2013-08-05
AR072934A1 (es) 2010-09-29
NZ584911A (en) 2011-08-26
BRPI0818928A2 (pt) 2017-05-16
PL2207808T3 (pl) 2013-11-29
KR101574814B1 (ko) 2015-12-04
EP2207808A1 (fr) 2010-07-21
HRP20130699T1 (hr) 2013-11-22
AU2008317724B2 (en) 2011-06-02
RU2513697C2 (ru) 2014-04-20
CO6270357A2 (es) 2011-04-20
US8163285B2 (en) 2012-04-24
SI2207808T1 (sl) 2013-09-30
RU2010122044A (ru) 2011-12-10

Similar Documents

Publication Publication Date Title
MA30965B1 (fr) Molecules de liaison a lingo et utilisation pharmaceutique de celles-ci
Raju et al. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes
Kimura et al. Expression of complement 3 and complement 5 in newt limb and lens regeneration
Becker-Santos et al. Nuclear factor I/B: a master regulator of cell differentiation with paradoxical roles in cancer
Phan et al. Single‐cell transcriptomic analysis of small and large wounds reveals the distinct spatial organization of regenerative fibroblasts
Saint-Pol et al. Regulation of the trafficking and the function of the metalloprotease ADAM10 by tetraspanins
MA31805B1 (fr) Molécules améliorées de liaison à nogo-a et utilisation pharmaceutique de celles-ci
Rahbar The discovery of glycated hemoglobin: a major event in the study of nonenzymatic chemistry in biological systems
Pätäri‐Sampo et al. Molecular basis of the glomerular filtration: nephrin and the emerging protein complex at the podocyte slit diaphragm
Hunger Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome–positive acute lymphoblastic anemia
Solomon et al. Light chain-associated amyloid deposits comprised of a novel κ constant domain
Hubmacher et al. Biogenesis of extracellular microfibrils: Multimerization of the fibrillin-1 C terminus into bead-like structures enables self-assembly
Huang et al. Effects of base sequence context on translesion synthesis past a bulky (+)-trans-anti-B [a] P-N 2-dG lesion catalyzed by the Y-family polymerase pol κ
ATE527279T1 (de) Zusammensetzungen und verfahren zur modulation des immunsystems
Jung et al. Association of clinical severity with FANCB variant type in Fanconi anemia
DiMaio et al. Isolation and characterization of circulating lymphatic endothelial colony forming cells
NO20061678L (no) NOGO-A bindingsmolekyler og funmsoytiske anvendelser derav
Sheikh et al. MeCP2 AT‐Hook1 mutations in patients with intellectual disability and/or schizophrenia disrupt DNA binding and chromatin compaction in vitro
Muntané et al. Analysis of synaptic gene expression in the neocortex of primates reveals evolutionary changes in glutamatergic neurotransmission
Lee et al. Meteorin-like is an injectable peptide that can enhance regeneration in aged muscle through immune-driven fibro/adipogenic progenitor signaling
Battle et al. ST7 is a novel low-density lipoprotein receptor-related protein (LRP) with a cytoplasmic tail that interacts with proteins related to signal transduction pathways
Babina et al. How “Neuronal” are human skin mast cells?
Gholaminejad et al. An integrative in silico study to discover key drivers in pathogenicity of focal and segmental glomerulosclerosis
Hattori et al. Increase of integrin-linked kinase activity in cultured podocytes upon stimulation with plasma from patients with recurrent FSGS
Tamimi et al. Identification of target genes regulated by FOXC1 using nickel agarose–based chromatin enrichment